HYDERABAD, India — Dr. Reddy’s Laboratories this week began shipping levofloxacin tablets in the U.S. market after receiving Food and Drug Administration approval for the antibiotic medication.
The company said Wednesday that it’s offering levofloxacin tablets, a bioequivalent generic version of Daiichi Sankyo Co.’s Levaquin, in strengths of 250 mg, 500 mg and 750 mg.
Dr. Reddy’s 250-mg and 500-mg levofloxacin tablets come in 50-count bottles, while the 750-mg tablets are available in 30-count bottles.
Levaquin had U.S. sales of about $1.1 billion for the 12 months ended in March, according to IMS Health data reported by Dr. Reddy’s. Part of a group of antibiotics called fluoroquinolones, levofloxacin is used to treat a wide variety of bacterial infections.
